MiMedx Group, Inc. (MDXG)
| Market Cap | 557.06M -45.3% |
| Revenue (ttm) | 389.42M +10.5% |
| Net Income | 30.70M -23.6% |
| EPS | 0.20 -25.9% |
| Shares Out | 148.95M |
| PE Ratio | 18.60 |
| Forward PE | 2,228.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,156,680 |
| Open | 3.800 |
| Previous Close | 3.780 |
| Day's Range | 3.730 - 3.880 |
| 52-Week Range | 3.025 - 7.990 |
| Beta | 1.46 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+73.8%) |
| Earnings Date | Apr 29, 2026 |
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The co... [Read more]
Financial Performance
In 2025, MiMedx Group's revenue was $418.63 million, an increase of 19.99% compared to the previous year's $348.88 million. Earnings were $48.58 million, an increase of 14.52%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MDXG stock is "Strong Buy." The 12-month stock price target is $6.5, which is an increase of 73.80% from the latest price.
News
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the Craig-Hallum...
MIMEDX Announces Launch of G4Derm® Plus
Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company's Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx...
MiMedx price target lowered to $6 from $7 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on MiMedx (MDXG) to $6 from $7 and keeps a Buy rating on the shares. The firm cites MiMedx’s Q1 results and guidance, which…
MiMedx price target lowered to $6 from $7 at Citizens
Citizens lowered the firm’s price target on MiMedx (MDXG) to $6 from $7 and keeps an Outperform rating on the shares. MiMedx is navigating a difficult 2026 transition year due…
MiMedx reports Q1 adjusted EPS (5c), consensus (4c)
Reports Q1 revenue $58.99M, consensus $65.8M. Joseph H. Capper, MiMedx (MDXG) Chief Executive Officer, commented, “The first quarter of 2026 was adversely impacted as new Medicare reimbursement polici...
MiMedx Group Earnings Call Transcript: Q1 2026
Q1 2026 saw net sales drop 33% year-over-year, driven by a 60% decline in wound care due to Medicare reimbursement changes, while surgical sales grew 13%. A $40 million cost reduction was implemented, and guidance anticipates sequential recovery and a return to profitability in the second half of the year.
MiMedx Group Quarterly report: Q1 2026
MiMedx Group has published its Q1 2026 quarterly earnings report on April 29, 2026.
MiMedx Group Earnings release: Q1 2026
MiMedx Group released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
MIMEDX Announces First Quarter 2026 Operating & Financial Results
Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29,...
MiMedx Group Proxy statement: Proxy filing
MiMedx Group filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MiMedx Group Proxy statement: Proxy filing
MiMedx Group filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first qu...
MiMedx price target lowered to $7 from $10 at Citizens
Citizens analyst David Turkaly lowered the firm’s price target on MiMedx (MDXG) to $7 from $10 and keeps an Outperform rating on the shares. MiMedx is implementing cost-cutting measures expected…
MiMedx price target lowered to $7 from $10 at Citizens
Citizens analyst David Turkaly lowered the firm’s price target on MiMedx (MDXG) to $7 from $10 and keeps an Outperform rating on the shares.
MiMedx price target lowered to $6 from $10 at Northland
Northland lowered the firm’s price target on MiMedx (MDXG) to $6 from $10 and keeps an Outperform rating on the shares. The firm is assuming a “conservative posture” with respect…
MiMedx price target lowered to $7 from $10 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on MiMedx (MDXG) to $7 from $10 and keeps a Buy rating on the shares. The firm is also lowering estimates following MiMedx’s restructuring…
MiMedx announces restructuring, cost reduction initiatives
MiMedx (MDXG) Group announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these ch...
MIMEDX Announces Restructuring and Cost Reduction Initiative
MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced a series of cost reduction initiatives intended to prioritize growth opp...
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWI...
MIMEDX Announces Launch of CHORIOFIX™
Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products
MiMedx announces commercial launch of AMNIOFIX Thyroid Shields
MiMedx (MDXG) Group announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension of the Company’s AMNIOFIX dehydrated human amnion/chorion membrane allografts. “Injuries to th...
MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields
MARIETTA, Ga., March 05, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extens...
MiMedx Group Earnings Call Transcript: Q4 2025
Record 2025 results with 20% revenue growth and strong cash flow, despite Medicare-driven disruption in wound care. Surgical business grew 20% and is expected to drive future growth, while guidance anticipates sequential revenue increases in 2026 and a return to double-digit growth by 2027.
MiMedx Group Earnings release: Q4 2025
MiMedx Group released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
MiMedx Group Annual report: Q4 2025
MiMedx Group has published its Q4 2025 annual report on February 25, 2026.